Phase I trial of ARQ 501, an Activated Checkpoint Therapy (ACT) agent, in patients with advanced solid tumors

3042 Background: ARQ 501 (β-Lapachone) is a novel anticancer agent that exhibits selective antitumor activity in a broad range of in vitro and in vivo preclinical models. It induces apoptosis in ca...